2025-05-13T10:09:25-05:00 2024-12-31 HAN GROUP LLC 1020 19TH STREET NW SUITE 800 WASHINGTON DC 20036 990 2024-01-01 521609875 RESEARCHAMERICA RESE 7037392577 241 18TH STREET SOUTH 501 ARLINGTON VA 22202 MICHAEL COBURN EXECUTIVE VICE PRESIDENT & COO 7037392577 2025-05-13 1 1 JENNIFER S HAN P00633304 2022937000 2025-05-13 2024 2025-03-06 01:10:19Z MARY WOOLLEY 241 18TH STREET SOUTH 501 ARLINGTON VA 22202 8881339 0 X WWW.RESEARCHAMERICA.ORG X 1989 DC ADVOCATES FOR SCIENCE, DISCOVERY AND INNOVATION TO ACHIEVE BETTER HEALTH FOR ALL. 35 34 45 65 0 0 4421376 7414381 2373400 0 181717 270061 20681 22362 6997174 7706804 273796 47759 0 0 4533207 4725105 0 0 754902 3106356 2813379 7913359 7586243 -916185 120561 11946167 13036982 2761062 3522649 9185105 9514333 X OUR NATION DEMANDS BOLD INVESTMENTS IN SCIENCE, TECHNOLOGY, AND PUBLIC HEALTH. WITH OUR 300+ MEMBER ORGANIZATIONS, THE RESEARCH!AMERICA ALLIANCE STANDS TOGETHER TO MAKE THE CASE TO MEET HEALTH THREATS WITH ROBUST AND UNRELENTING ADVOCACY FOR RESEARCH INVESTMENT. IN COLLABORATION WITH OUR MEMBERS AND PARTNERS, WE CONTINUED TO PUSH THE PACE OF MEDICAL AND PUBLIC HEALTH PROGRESS TO DELIVER BETTER HEALTH FOR ALL. THROUGH THE RESEARCH AMERICA ALLIANCE, OUR PARTNERS AND SUPPORTERS HAVE CLOSELY MONITORED PUBLIC SENTIMENT, CRAFTED IMPACTFUL MESSAGES, DEVELOPED POLICY CHAMPIONS, AND SHARED TIMELY KNOWLEDGE AND INSIGHTS CRITICAL TO EFFECTIVE ADVOCACY. AS ADVOCATES FOR RESEARCH, WE PLAY A PIVOTAL ROLE IN SHAPING A FUTURE THAT TRANSCENDS THE LIMITATIONS OF TODAY, PURSUING THE BOUNDLESS PROGRESS IN MEDICAL AND HEALTH RESEARCH, AND SCIENCE AND TECHNOLOGY WRIT LARGE, MADE CAPABLE BY THE DEDICATION OF BOTH PUBLIC AND PRIVATE SECTORS. 0 0 3097878 ADVOCATING FOR SCIENCE, DISCOVERY, AND INNOVATION TO ACHIEVE BETTER HEALTH FOR ALL:THE RESEARCH!AMERICA ALLIANCE IS A DRIVING FORCE IN ADVOCATING WITH ONE VOICE TO REPRESENT THE R&D ECOSYSTEM. WE ADVOCATE INCREASED FUNDING FOR OUR NATION'S MEDICAL, HEALTH AND SCIENTIFIC R&D FOCUSED FEDERAL AGENCIES. WE WORK WITH OUR MEMBERS AND INDIVIDUAL ADVOCATES TO ENCOURAGE CONGRESS AND THE ADMINISTRATION TO SUPPORT FAST-PACED MEDICAL PROGRESS AND ADVANCES IN PUBLIC HEALTH. IN 2024, WE FACILITATED DISCUSSION WITH CONGRESSIONAL STAFF WORKING ON CURES 2.1, THE THIRD GENERATION OF BIPARTISAN LEGISLATION FOCUSED ON STRENGTHENING THE DISCOVERY, DEVELOPMENT AND DELIVERY PIPELINE. OUR ADVOCACY EFFORTS IN 2024 INCLUDED 51 MEETINGS WITH CONGRESSIONAL OFFICES, AND 26 MEETINGS WITH ADMINISTRATION OFFICIALS. WE OBTAINED 1,548 MEDIA MENTIONS AND CONDUCTED 54 ALLIANCE MEMBER DISCUSSIONS TO INFORM OUR MEMBERS. TO PROVIDE OUR MEMBERS WITH ADVOCACY TOOLS, WE DEVELOPED 33 BRIEFING PAPERS AND ENGAGEMENT RESOURCES, INCLUDING UPDATED FACT SHEETS ON DISEASE THREATS AND EMERGING HEALTH TECHNOLOGIES. 785252 ADVOCACY PROGRAMS:WE ANNUALLY HOST SEVERAL PARTNER PROGRAMS EACH YEAR, HIGHLIGHTING OUR CONVENING POWER AND ABILITY TO IDENTIFY AND FOCUS ATTENTION ON TIMELY RESEARCH AND DEVELOPMENT POLICY RELATED TOPICS. IN 2024 THE NATIONAL HEALTH RESEARCH FORUM HOSTED THOUGHT-PROVOKING DISCUSSIONS AROUND EXPLORING INNOVATIONS IN HEALTH SYSTEMS RESEARCH, STRENGTHENING THE STEM WORKFORCE, ACCELERATING INNOVATION THROUGH CLINICAL TRIALS, MENTAL HEALTH, BUILDING TRUST, ARTIFICIAL INTELLIGENCE (AI) AND DRUG DEVELOPMENT, AND MORE! THIS EVENT FEATURED 40 SPEAKERS, INCLUDING 11 HIGH-RANKING GOVERNMENT OFFICIALS. FOLLOWING THE 2024 ELECTIONS, WE HOSTED OUR BI-ANNUAL POST-ELECTION BRIEFING FOR AN IN-THE-MOMENT DISCUSSION ABOUT THE 2024 ELECTION OUTCOMES AND IMPLICATIONS ON RESEARCH AND DEVELOPMENT WITH THE 119TH CONGRESS. 769689 BOLSTERING OUR NATION'S R&D CAPACITY:THE SCIENCE AND TECHNOLOGY ACTION COMMITTEE (STAC), AN INITIATIVE THAT BRINGS TOGETHER NONPROFIT, ACADEMIC, FOUNDATION, AND CORPORATE LEADERS, WITH RESEARCH!AMERICA IN A LEADING ROLE, AIMS TO CHAMPION A BOLDER APPROACH TO BOLSTERING OUR NATION'S R&D CAPACITY. BUILDING ON MOMENTUM GENERATED FROM THE DECEMBER 2023 RELEASE OF STAC'S STATE OF SCIENCE IN AMERICA REPORT, WE CREATED A TASK FORCE COMPRISED OF NEARLY 70 INFLUENTIAL LEADERS ACROSS SCIENCE, ACADEMIA, INDUSTRY, PHILANTHROPY, AND POLICY. THIS TASK FORCE'S MISSION WAS TO DEVELOP A VISION FOR AMERICAN SCIENCE AND TECHNOLOGY TO EQUIP POLICYMAKERS IN WASHINGTON, D.C., WITH A CLEAR VISION FOR THE FUTURE OF SCIENCE AND TECHNOLOGY, ALONG WITH ACTIONABLE POLICY RECOMMENDATIONS. 662616 GLOBAL HEALTH R&D ADVOCACY:IN 2024, RESEARCH!AMERICA EXPANDED ITS GLOBAL HEALTH R&D ADVOCACY PROGRAM, COMPLETING THE THIRD YEAR OF A MULTI-YEAR GRANT PROJECT. THE GRANT WAS EXTENDED FOR AN ADDITIONAL THREE YEARS. THE GOAL OF THE PROJECT IS TO INCREASE UNITED STATES GOVERNMENT NON-OFFICIAL DEVELOPMENT ASSISTANCE (ODA) FUNDING FOR GLOBAL HEALTH RESEARCH & DEVELOPMENT, WITH PARTICULAR EMPHASIS ON ADVANCING INNOVATIVE CROSS-SECTOR PARTNERSHIPS AND OTHER EFFICIENCY-CREATING R&D STRATEGIES, INCLUDING PLATFORM TECHNOLOGIES AND GLOBAL CLINICAL TRIAL NETWORKS. 297232 47759 SCIENCE OUTREACH AND CIVIC ENGAGEMENT:THE CIVIC ENGAGEMENT MICROGRANT PROGRAM IN 2024 WAS OUR 7TH YEAR EMPOWERING EARLY-CAREER SCIENCE CIVIC ENGAGEMENT THROUGH MICROGRANTS. THE PROGRAM WAS HIGHLY COMPETITIVE WITH 26 MICROGRANTS FUNDED FROM ACROSS THE COUNTRY. RESEARCH!AMERICA ALSO RELEASED RECOMMENDATIONS ABOUT HOW TO INCLUDE PUBLIC ENGAGEMENT SKILLS IN STEMM GRADUATE TRAINING BASED ON INPUT FROM A GROUP OF UNIVERSITY AND FOUNDATION LEADERS. WE LOOK FORWARD TO CONTINUING TO BUILD ON THESE RECOMMENDATIONS. 345274 OTHER PROGRAMS 1305122 47759 5957941 1 1 0 1 0 0 0 0 0 1 1 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 24 0 1 45 1 0 0 0 0 0 0 0 0 0 0 0 0 X 35 34 0 0 0 0 1 1 1 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AK AR CA CO CT FL GA HI IL KS KY ME MD MA MI MN MS NV NH NJ NM NY NC ND OH OK OR PA RI SC TN VA WA WV WI X X MICHAEL COBURN 7037392577 241 18TH STREET SOUTH 501 ARLINGTON VA 22202 MARY WOOLLEY PRESIDENT & CHIEF EXECUTIVE OFFICER 50.00 X X 657883 0 76572 SUDIP PARIKH PHD CHAIR 3.00 X X 0 0 0 GEORGES BENJAMIN MD VICE CHAIR 2.00 X X 0 0 0 HAROLD L PAZ MD MS SECRETARY 2.00 X X 0 0 0 E ALBERT REECE MD PHD MBA DIRECTOR 1.00 X X 0 0 0 NANCY BROWN TREASURER 2.00 X X 0 0 0 AMY COMSTOCK RICK JD TREASURER(THRU MAR);DIR.(THRU NOV) 1.00 X X 0 0 0 DEBORAH DEAS MD MPH DIRECTOR 1.00 X 0 0 0 HON CHARLIE DENT DIRECTOR (THRU APRIL) 1.00 X 0 0 0 MIKAEL DOLSTEN MD PHD DIRECTOR 1.00 X 0 0 0 VICTOR J DZAU MD DIRECTOR 1.00 X 0 0 0 KAFUI DZIRASA MD PHD DIRECTOR 1.00 X 0 0 0 AYMAN EL-MOHANDES MBBCH MD DIRECTOR 1.00 X 0 0 0 ARTHUR C EVANS JR PHD DIRECTOR 1.00 X 0 0 0 JULIE GERBERDING MD MPH DIRECTOR 1.00 X 0 0 0 DARIO GIL PHD DIRECTOR (THRU APRIL) 1.00 X 0 0 0 HON BART GORDON DIRECTOR 1.00 X 0 0 0 CELINE GOUNDER MD SCM DIRECTOR 1.00 X 0 0 0 MARY JC HENDRIX PHD DIRECTOR 1.00 X 0 0 0 HON RUSH D HOLT PHD DIRECTOR 1.00 X 0 0 0 KAREN KNUDSEN PHD DIRECTOR 1.00 X 0 0 0 LAURA MAGANA PHD DIRECTOR 1.00 X 0 0 0 MARK B MCCLELLAN MD PHD DIRECTOR 1.00 X 0 0 0 MICHELLE MCMURRY-HEATH MD PHD DIRECTOR 1.00 X 0 0 0 JESSICA L MEGA MD MPH DIRECTOR 1.00 X 0 0 0 HERBERT PARDES MD DIRECTOR (THRU APRIL) 1.00 X 0 0 0 MARY PITTMAN DRPH DIRECTOR 1.00 X 0 0 0 CLAIRE POMEROY MD DIRECTOR 1.00 X 0 0 0 GUILLERMO WILLY J PRADO PHD DIRECTOR (THRU APRIL) 1.00 X 0 0 0 DEREK K RAPP DIRECTOR 1.00 X 0 0 0 JOHN REED MD PHD DIRECTOR 1.00 X 0 0 0 DAVID REESE MD DIRECTOR 1.00 X 0 0 0 LAING ROGERS DIRECTOR (THRU APRIL) 1.00 X 0 0 0 LEWIS G SANDY MD FACP DIRECTOR 1.00 X 0 0 0 HON DONNA SHALALA PHD DIRECTOR 1.00 X 0 0 0 RAVI THADHANI MD MPH DIRECTOR 1.00 X 0 0 0 DEBORAH TRAUTMAN PHD RN FAAN DIRECTOR 1.00 X 0 0 0 M ROY WILSON MD DIRECTOR 1.00 X 0 0 0 KEITH YAMAMOTO PHD DIRECTOR 1.00 X 0 0 0 CYNTHIA ZAGIEBOYLO DIRECTOR 1.00 X 0 0 0 ELIAS ZERHOUNI MD DIRECTOR 1.00 X 0 0 0 MICHAEL COBURN EXECUTIVE VICE PRESIDENT & COO 45.00 X 318711 0 38944 ELEANOR DEHONEY SR. VP OF POLICY & ADVOCACY 45.00 X 282567 0 36057 JENNIFER LURAY SR VP STRATEGY & PUBLIC ENGAGEMENT 45.00 X 251435 0 50464 SHEILA MURPHY VP - ADVOCACY PROGRAMS 45.00 X 228252 0 21196 ANNE MANDEVILLE VP DEVELOPMENT & MEMBERSHIP 45.00 X 220618 0 24320 KATHERINE GOODE SENIOR DIRECTOR - DEVELOPMENT 45.00 X 151994 0 16306 2111460 0 263859 10 0 1 0 FAEGRE DRINKER BIDDLE & REATH LLP 1500 K STREET NW 1100 WASHINGTON DC 20005 POLICY RES/STRAT. DEVELOPMENT 255000 TEAM SUBJECT MATTER LLC 1201 NEW YORK AVE NW SUITE 900 WASHINGTON DC 20005 ADVOCACY/COMMUNICATIONS 238117 KEEFE SINGISER PARTNERS 4416 CHESAPEAKE STREET NW WASHINGTON DC 22016 GOVERNMENT RELATIONS 225000 AVOQ LLC 1201 NEW YORK AVE NW SUITE 900 WASHINGTON DC 20005 ADVOCACY/COMMUNICATIONS 221677 KOUNTOUPES DENHAM CARR & REID 607 14TH STREET NW 750 WASHINGTON DC 20005 GOVERNMENT RELATIONS 180000 7 1369195 6045186 38966 7414381 190478 190478 44504 22142 22362 22362 22362 1231976 1152393 79583 79583 79583 7706804 0 0 292423 X 47759 47759 1092110 473565 362442 256103 2944449 2332237 277974 334238 188785 158897 15208 14680 250422 189826 31327 29269 249339 175734 38274 35331 651 651 77208 77208 286719 286719 1573 1573 1431976 1408478 10641 12857 81860 81860 31325 26746 1972 2607 118609 96014 7721 14874 223881 183582 11194 29105 85517 75587 728 9202 271282 243219 27651 412 128 128 74867 61391 3743 9733 19163 15714 958 2491 SURVEYS 57700 57700 DUES AND SUBSCRIPTIONS 43158 36548 3619 2991 TAXES & LICENSES 7762 6365 388 1009 7586243 5957941 873400 754902 605029 253589 1489562 2897691 1883107 1590112 5953 244 20888 48168 705435 526895 240750 178540 6124623 6496473 1576255 1572165 11946167 13036982 610583 730668 225579 949051 1924900 1842930 2761062 3522649 X 1442725 688454 7742380 8825879 9185105 9514333 11946167 13036982 X 120561 209304 -637 X X 0 1 X 1 0 X 2393648 7916222 3958577 4421376 7414381 26104204 2393648 7916222 3958577 4421376 7414381 26104204 10727683 15376521 66202 73024 135771 243324 228427 746748 14684 631 23 10 15348 26866300 10419212 0.57230 0.53700 X SCHEDULE A, PART II, LINE 10, EXPLANATION OF OTHER INCOME: MISCELLANEOUS - 2020 AMOUNT: $ 14,684. 2021 AMOUNT: $ 631. 2022 AMOUNT: $ 23. 2023 AMOUNT: $ 10. 2024 AMOUNT: $ 0. RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 9781 276938 286719 7299524 7586243 529312 132328 0 0 376049 459239 545668 529312 1910268 2865402 241801 328386 327738 286719 1184644 94012 114810 136417 132328 477567 716351 8369 9590 11071 9781 38811 4997988 200000 345521 250000 5293509 4404539 200000 643449 250000 4997988 5393479 200000 -988940 200000 4404539 100000 5100000 193479 5393479 100000 100000 1.00000 0 0 524438 411883 112555 125721 92871 32850 55276 22141 33135 178540 DEPOSITS 20888 DEFERRED COMPENSATION INVESTMENTS 1007113 RIGHT-OF-USE ASSETS - OPERATING LEASES 544164 1572165 DEFERRED COMPENSATION 1007113 OPERATING LEASE LIABILITY 827539 FINANCE LEASE LIABILITY 8278 1842930 X 7998348 209304 61671 22142 293117 7705231 1573 1573 7706804 7669120 61671 22779 84450 7584670 1573 1573 7586243 PART V, LINE 4: THE BOARD OF DIRECTORS HAS DESIGNATED AN AMOUNT OF $399,472 FOR A FUTURE USE TO BE DETERMINED AT A LATER TIME AND ONLY UPON APPROVAL OF THE BOARD. RESEARCH!AMERICA'S ENDOWMENT WAS ESTABLISHED IN FEBRUARY 2020 AND CONSISTS OF ONE FUND, ESTABLISHED TO SUPPORT THE GORDON AND LLURA GUND LEADERSHIP AWARD PRESENTED BY RESEARCH!AMERICA ANNUALLY AT ITS ADVOCACY AWARDS EVENT. IN 2021, JOHNSON & JOHNSON ESTABLISHED A PERMANENT ENDOWMENT TO PROVIDE SPONSORSHIP SUPPORT FOR THE PUBLIC HEALTH AWARDS AS PART OF THE ADVOCACY AWARDS EVENT. PART X, LINE 2: THE ORGANIZATION FOLLOWS THE AUTHORITATIVE GUIDANCE RELATING TO ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES INCLUDED IN ACCOUNTING STANDARDS CODIFICATION TOPIC 740-10, INCOME TAXES. THESE PROVISIONS PROVIDE CONSISTENT GUIDANCE FOR THE ACCOUNTING FOR UNCERTAINTY IN INCOME TAXES RECOGNIZED IN AN ENTITY'S FINANCIAL STATEMENTS AND PRESCRIBE A THRESHOLD OF "MORE LIKELY THAN NOT" FOR RECOGNITION AND DERECOGNITION OF TAX POSITIONS TAKEN OR EXPECTED TO BE TAKEN IN A TAX RETURN. IT IS THE ORGANIZATION'S POLICY TO RECOGNIZE INTEREST AND/OR PENALTIES RELATED TO UNCERTAIN TAX POSITIONS, IF ANY, IN INCOME TAX EXPENSES. THE ORGANIZATION PERFORMED AN EVALUATION OF UNCERTAIN TAX POSITIONS FOR THE YEAR ENDED DECEMBER 31, 2024, AND DETERMINED THAT THERE WERE NO MATTERS THAT WOULD REQUIRE RECOGNITION ON THE FINANCIAL STATEMENTS OR THAT MAY HAVE ANY EFFECT ON ITS TAX-EXEMPT STATUS. THE STATUTE OF LIMITATIONS GENERALLY REMAINS OPEN FOR THREE TAX YEARS WITH THE U.S. FEDERAL JURISDICTION OR THE VARIOUS STATES AND LOCAL JURISDICTIONS IN WHICH THE ORGANIZATION FILES TAX RETURNS. PART XI, LINE 2D - OTHER ADJUSTMENTS: RENT EXPENSES 22,142. PART XII, LINE 2D - OTHER ADJUSTMENTS: RENT EXPENSES 22,142. A WRITE-OFF OF A PREVIOUS PLEDGE 637. X X X X X 0 0 0 0 0 0 0 1 0 MARY WOOLLEY PRESIDENT & CHIEF EXECUTIVE OFFICER 571946 0 83220 0 2717 0 50600 0 25972 0 734455 0 0 0 MICHAEL COBURN EXECUTIVE VICE PRESIDENT & COO 299994 0 16000 0 2717 0 25650 0 13294 0 357655 0 0 0 ELEANOR DEHONEY SR. VP OF POLICY & ADVOCACY 264851 0 15000 0 2716 0 22763 0 13294 0 318624 0 0 0 JENNIFER LURAY SR VP STRATEGY & PUBLIC ENGAGEMENT 219605 0 15000 0 16830 0 21551 0 28913 0 301899 0 0 0 SHEILA MURPHY VP - ADVOCACY PROGRAMS 216252 0 12000 0 0 0 18376 0 2820 0 249448 0 0 0 ANNE MANDEVILLE VP DEVELOPMENT & MEMBERSHIP 207618 0 13000 0 0 0 17627 0 6693 0 244938 0 0 0 KATHERINE GOODE SENIOR DIRECTOR - DEVELOPMENT 151994 0 0 0 0 0 12145 0 4161 0 168300 0 0 0 PART I, LINE 7 THE COMPENSATION COMMITTEE ESTABLISHES PERFORMANCE METRICS FOR THE CEO AT THE START OF THE YEAR WITH LEVELS OF ACHIEVEMENT DETERMINED (MEETS, EXCEEDS AND STRETCH GOALS). FOLLOWING THE CLOSE OF THE YEAR, THE COMMITTEE REVIEWS RESULTS WITH PERFORMANCE METRICS TO DETERMINE OVERALL LEVEL OF PERFORMANCE. THE COMMITTEE ENGAGES A COMPENSATION CONSULTANT TO REVIEW THE MARKET COMPARISON FOR TOTAL COMPENSATION. THE BONUS FOR THE CEO IS CALCULATED TO PLUS UP TOTAL COMPENSATION TO THE LEVEL THE COMMITTEE DETERMINES SO THAT THE TOTAL OF BASE SALARY PLUS BONUS EQUALS THE AGREED UPON LEVEL OF COMPENSATION. THE FOLLOWING EMPLOYEES RECEIVED BONUSES IN 2024: 1. MARY WOOLLEY -$83,220 2. MICHAEL COBURN -$16,000 3. ELEANOR DEHONEY -$15,000 4. JENNIFER LURAY -$15,000 5. SHEILA MURPHY -$12,000 6. ANNE MANDEVILLE -$13,000 X 2 32396 FMV X BEVERAGES 1 6570 FMV 0 1 0 PART I, COLUMN (B): THE TOTAL IN COLUMN (B) REPRESENTS THE TOTAL NUMBER OF CONTRIBUTIONS RECEIVED. FORM 990, PART VI, SECTION A, LINE 6 RESEARCH!AMERICA IS A MEMBERSHIP ORGANIZATION. MEMBERSHIP IS OPEN TO ANY ORGANIZATION, PROFESSIONAL SOCIETY, ASSOCIATION, CORPORATION, INSTITUTION, OTHER ENTITY OR INDIVIDUAL WHICH IS INTERESTED IN AND SUPPORTIVE OF THE MISSION OF RESEARCH!AMERICA - TO MAKE RESEARCH FOR HEALTH A HIGHER NATIONAL PRIORITY. MEMBERS ARE APPROVED BY THE BOARD OF DIRECTORS. FORM 990, PART VI, SECTION A, LINE 7A EACH INSTITUTION MEMBER HAS ONE VOTE ON MATTERS SUBJECT TO A VOTE BY THE MEMBERSHIP. MEMBERS ELECT THE BOARD OF DIRECTORS AT THE ANNUAL MEETING. FORM 990, PART VI, SECTION A, LINE 7B MEMBERS MAY BE ASKED TO VOTE ON MATTERS OUTLINED IN THE BYLAWS (ELECTION OF DIRECTORS AND DISSOLUTION OR AMENDMENTS TO THE BYLAWS). FORM 990, PART VI, SECTION B, LINE 11B THE DRAFT FORM 990 IS PRESENTED TO THE AUDIT COMMITTEE IN CONJUNCTION WITH THE PRESENTATION OF THE AUDIT REPORT FOR THE YEAR ENDED. ONCE APPROVED BY THE COMMITTEE, THE DRAFT FORM 990 IS DISTRIBUTED TO THE BOARD OF DIRECTORS, WHO ARE GIVEN A 48-HOUR PERIOD TO RESPOND WITH ANY ISSUES OR EDITS PRIOR TO FILING WITH THE INTERNAL REVENUE SERVICE. FORM 990, PART VI, SECTION B, LINE 12C THE AUDIT COMMITTEE IS CHARGED WITH OVERSIGHT OF ADHERENCE TO THE CONFLICT-OF-INTEREST POLICY. ANNUALLY, EACH MEMBER OF THE BOARD OF DIRECTORS AND EACH MEMBER OF STAFF IS REQUIRED TO REVIEW THE POLICY AND SUBMIT A SIGNED DISCLOSURE STATEMENT. THE AUDIT COMMITTEE REVIEWS AND REPORTS TO THE BOARD OF DIRECTORS ANY POTENTIAL CONFLICT OF INTEREST. ANY DIRECTOR WITH A DISCLOSED CONFLICT SHALL RECUSE THEMSELVES FROM DELIBERATIONS ON ACTIONS THAT MAY BE CONSTRUED AS A CONFLICT OF INTEREST. FORM 990, PART VI, SECTION B, LINE 15 THE COMPENSATION COMMITTEE IS CHARGED WITH OVERSIGHT OF EXECUTIVE COMPENSATION. THE COMPENSATION COMMITTEE, IN CONSULTATION WITH THE BOARD CHAIR, ESTABLISHES PERFORMANCE METRICS FOR THE CEO. FOLLOWING THE CLOSE OF THE YEAR, THE COMPENSATION COMMITTEE REVIEWS RESULTS TO DETERMINE THE OVERALL LEVEL OF PERFORMANCE. A THIRD-PARTY COMPENSATION CONSULTANT IS ENGAGED TO REVIEW MARKET COMPENSATION FOR THE PRESIDENT AND CEO AND KEY MANAGEMENT EMPLOYEES. COMPENSATION FOR THE PRESIDENT AND CEO AND KEY EMPLOYEES FOR 2024 WAS REVIEWED AND APPROVED BY THE COMPENSATION COMMITTEE ON FEBRUARY 27, 2024. THE COMMITTEE SUBMITTED ITS RECOMMENDATION TO THE BOARD OF DIRECTORS, WITH THE BOARD APPROVING THE COMMITTEE'S RECOMMENDATIONS AT THE MARCH 14, 2024, BOARD OF DIRECTORS MEETING. RESEARCH!AMERICA'S COMPENSATION COMMITTEE MOST RECENTLY MET ON FEBRUARY 6, 2025, TO REVIEW PERFORMANCE AND COMPENSATION OF THE PRESIDENT & CEO AND REVIEW COMPENSATION OF KEY EMPLOYEES FOR 2025. FORM 990, PART VI, SECTION C, LINE 19 CODE OF ETHICS, CONFLICT OF INTEREST AND WHISTLEBLOWER POLICY AND FINANCIAL INFORMATION IS AVAILABLE ON RESEARCH!AMERICA'S WEB SITE, THESE AND OTHER GOVERNING DOCUMENTS ARE ALSO AVAILABLE UPON REQUEST. FORM 990, PART IX, LINE 11G PROGRAM CONSULTING: PROGRAM SERVICE EXPENSES 1,341,366. MANAGEMENT AND GENERAL EXPENSES 0. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,341,366. CONSULTANT SERVICES: PROGRAM SERVICE EXPENSES 67,112. MANAGEMENT AND GENERAL EXPENSES 10,641. FUNDRAISING EXPENSES 12,857. TOTAL EXPENSES 90,610. FORM 990, PART XI, LINE 9: A WRITE-OFF OF A PREVIOUS PLEDGE -637. FORM 990, PART XII, LINE 2C: THE PROCESS REMAINS UNCHANGED FROM THE PRIOR YEAR. FORM 990, PART VIII, RECLASSIFICATION OF PROGRAM SERVICE REVENUE: IN PRIOR YEARS, THE ORGANIZATION REPORTED CERTAIN REVENUE AS PROGRAM SERVICE REVENUE. AFTER FURTHER REVIEW OF THE NATURE OF ITS PROGRAM ACTIVITIES AND MEMBERSHIP DUES, THE ORGANIZATION DETERMINED THAT THIS REVENUE MORE ACCURATELY REFLECTS CONTRIBUTIONS RATHER THAN FEES FOR SERVICES PROVIDED. ACCORDINGLY, FOR THE CURRENT YEAR, THE ORGANIZATION HAS REPORTED ALL SUCH REVENUE AS CONTRIBUTIONS ON PART VIII, LINE 1. NO PROGRAM SERVICE REVENUE IS REPORTED FOR THIS YEAR. THIS CHANGE REFLECTS A MORE ACCURATE CLASSIFICATION BASED ON THE SUBSTANCE OF THE TRANSACTIONS.